- LDL ("bad") should be low; HDL ("good") should be high; total cholesterol is the two combined.
- The LDL target is risk-stratified: <1.4 mmol/l (very high risk) up to <3.0 mmol/l (no risk conditions).
- HDL: >1.0 mmol/l (men), >1.2 mmol/l (women); triglycerides <1.7 mmol/l.
- Some mushroom extracts both lower LDL and raise HDL - a multi-pathway formula is preferable to single powders.
Cholesterol is essential — so why meet a "norm"?
Cholesterol is everywhere; a large part of it is even in the brain. It participates in neuron activity (memory), hormone production (cortisol, testosterone and others), the absorption of vitamins (A, D, E and K), and much more. So cholesterol is needed in every cell — although we call it "bad" — and without it we could not live. The problem is that too much LDL ("bad") cholesterol is a harbinger of heart disease.
Confusing cholesterol results
Let us identify which cholesterol is which, then examine the norm by the cholesterol table.
- LDL — low-density lipoprotein — the "bad" cholesterol. The less of it in the blood, the better. LDL can clog blood vessels.
- HDL — high-density lipoprotein — the "good" cholesterol. The more, the better. HDL helps remove LDL, so their ratio matters.
- Total cholesterol — LDL and HDL added together.
Say your LDL is high and you are already thinking about how to lower it quickly — but if your HDL is also high, that means it is helping remove the bad. So HDL reduces the likelihood of circulatory disease.
Cholesterol norm — table
Important: the norms below are in mmol/L. If your blood-test results are in mg/dL, see the mg/dL norms. The most important norm is LDL cholesterol — choose your risk group to know what your level should be.2
| Risk group | LDL target |
|---|---|
| Atherosclerosis, familial hypercholesterolaemia, diabetes with organ damage, other very-high-risk states | < 1.4 mmol/L |
| Diabetes >10 years, chronic kidney disease, blood pressure ≥180/110 mmHg, other high risk | < 1.8 mmol/L |
| Diabetes <10 years, type 2 diabetes | < 2.6 mmol/L |
| No risk group (no conditions) | < 3.0 mmol/L |
HDL cholesterol norm
For HDL ("good") cholesterol, higher is better: above 1.0 mmol/L for men and above 1.2 mmol/L for women, though above 1.5 mmol/L is preferable. Triglycerides should be below 1.7 mmol/L (or below 2.3 mmol/L if tested after eating).
Which mushroom extracts lower cholesterol without side effects, so the level becomes normal?
There are medicinal mushrooms that not only lower the bad cholesterol but also raise the good — restoring the cholesterol balance. These dried polysaccharide extracts are among the best cholesterol supplements. To achieve results, it is very important to use the highest-quality, strong and reliable products — a precision multi-pathway formula rather than simple powders.
Some mushroom extracts both lower LDL and raise HDL. A precision multi-pathway formula is studied as more effective than simple powders.
AURI 25 by Zenius Labs™ →Total cholesterol should be below 5.0 mmol/l. LDL ("bad") below 3.0 mmol/l for people without risk factors — lower (1.4–1.8 mmol/l) for those with heart disease or high risk. HDL ("good") above 1.0 mmol/l for men and 1.2 mmol/l for women. These are guidelines and vary by age and risk.
LDL (low-density lipoprotein) is the "bad" cholesterol — the less the better, as it can clog blood vessels. HDL (high-density lipoprotein) is the "good" cholesterol — the more the better, as it helps remove LDL. Total cholesterol is the two combined.
Yes. For many people, adjusting diet, increasing physical activity, and taking quality mushroom-polysaccharide supplements is enough. It is important to choose not simple powders but a concentrated multi-extract formula such as AURI 25 by Zenius Labs™.
The LDL target is risk-stratified: below 1.4 mmol/l for very-high-risk states (atherosclerosis, familial hypercholesterolaemia, diabetes with organ damage), below 1.8 for high risk, below 2.6 for type 2 diabetes, and below 3.0 for those with no risk conditions.
- Yin CM et al. Physicochemical Properties and Antioxidant Activity of Natural Melanin Extracted from the Wild Wood Ear Mushroom, Auricularia auricula (Agaricomycetes). International journal of medicinal mushrooms. 2022. PubMed
- Liu X et al. Comprehensive utilization of edible mushroom Auricularia auricula waste residue-Extraction, physicochemical properties of melanin and its antioxidant activity. Food science & nutrition. 2019. PubMed
- González-Bonilla A et al. Dietary Supplementation with Oyster Culinary-Medicinal Mushroom, Pleurotus ostreatus (Agaricomycetes), Reduces Visceral Fat and Hyperlipidemia in Inhabitants of a Rural Community in Mexico. International journal of medicinal mushrooms. 2022. PubMed
- Abrams DI et al. Antihyperlipidemic effects of Pleurotus ostreatus (oyster mushrooms) in HIV-infected individuals taking antiretroviral therapy. BMC complementary and alternative medicine. 2011. PubMed
- Belobrajdic DP et al. β-Glucan content and in vitro bile-acid binding capacity of Agaricus bisporus and Pleurotus spp. Food & function. 2024. PubMed
- Maheshwari G et al. Characterization of the Nutritional Composition of a Biotechnologically Produced Oyster Mushroom and its Physiological Effects in Obese Zucker Rats. Molecular nutrition & food research. 2020. PubMed
- Sato M et al. Long-term intake of Tamogi-take mushroom (Pleurotus cornucopiae) mitigates age-related cardiovascular dysfunction and extends healthy life expectancy. npj aging. 2025. PubMed
- Gong J et al. Efficacy and safety of sugarcane policosanol on dyslipidemia: A meta-analysis of randomized controlled trials. Molecular nutrition & food research. 2018. PubMed
- Chen JT et al. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy. 2005. PubMed
- Millán J et al. Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: A meta-analysis of randomised controlled trials. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis. 2016. PubMed
- Singh DK et al. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. The Journal of pharmacology and experimental therapeutics. 2006. PubMed
- Castaño G et al. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clinical drug investigation. 2003. PubMed
- Xiong Z et al. An overview of the bioactivity of monacolin K / lovastatin. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2019. PubMed
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) et al. Scientific Opinion on additional scientific data related to the safety of monacolins from red yeast rice submitted pursuant to Article 8(4) of Regulation (EC) No 1925/2006. EFSA journal. European Food Safety Authority. 2025. PubMed
- Peng D et al. Original Research: The Effects of Red Yeast Rice Supplementation on Cholesterol Levels in Adults. The American journal of nursing. 2017. PubMed
- Gerards MC et al. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain – a systematic review and meta-analysis. Atherosclerosis. 2015. PubMed
- Cicero AFG et al. Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review. Nutrients. 2023. PubMed
- Buzzelli L et al. Alternative lipid lowering strategies: State-of-the-art review of red yeast rice. Fitoterapia. 2024. PubMed
- Hermans MP et al. The antihyperlipidemic effect of a combined supplement of standardized dry extracts of amla (Emblica officinalis), walnut (Juglans regia), olive (Olea europaea) and red yeast rice (Monascus purpureus) powder: Reduction in circulatory low-density lipoprotein-cholesterol (LDL-C) and remnant cholesterol (RC) levels in patients with hypercholesterolemia. Frontiers in pharmacology. 2023. PubMed
- Sun HJ et al. Deficiency of neutral cholesterol ester hydrolase 1 (NCEH1) impairs endothelial function in diet-induced diabetic mice. Cardiovascular diabetology. 2024. PubMed
- Park C et al. Disturbed flow induces reprogramming of endothelial cells to immune-like and foam cells under hypercholesterolaemia during atherogenesis. Cardiovascular research. 2025. PubMed
- Zhang S et al. Natural products: The role and mechanism in low-density lipoprotein oxidation and atherosclerosis. Phytotherapy research : PTR. 2021. PubMed
- Wang J et al. DBZ (Danshensu Bingpian Zhi), a Novel Natural Compound Derivative, Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice. Journal of the American Heart Association. 2017. PubMed